Chemical linkers in antibody-drug conjugates (ADCs) /:
The covalent conjugation of potent cytotoxic agents to monoclonal antibodies, known as antibody-drug conjugates (ADCs) is a powerful approach in the field of targeted treatment of cancer. Clearly, both monoclonal antibody and cytotoxic payload are crucial elements in determining the clinical value o...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge :
Royal Society of Chemistry,
[2022]
|
| Schriftenreihe: | ISSN.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | The covalent conjugation of potent cytotoxic agents to monoclonal antibodies, known as antibody-drug conjugates (ADCs) is a powerful approach in the field of targeted treatment of cancer. Clearly, both monoclonal antibody and cytotoxic payload are crucial elements in determining the clinical value of an ADC and have receive ample attention. However, the structural element connecting the two -the chemical linker- also plays an essential role in mode-of-action, efficacy, pharmacokinetics and safety profile of an ADC, but is often underappreciated in considerations of ADC design.Chemical Linkers in Antibody-Drug Conjugates aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody ratio, for stability, for release mechanism of payload, for pharmacokinetics, for stability determination, and for efficacy and safety. Ideal for postgraduate students and active researchers in drug discovery and development, this book provides a comprehensive description of linkers used in ADCs (clinical and late preclinical), insight into key quality attributes of linkers for ADCs, and aids the reader in understanding the role of linker chemistry and designing new ADCs. |
| Beschreibung: | 1 online resource (xvi, 460 pages) |
| Bibliographie: | Includes bibliographical references and index |
| ISBN: | 9781839165160 1839165162 |
Internformat
MARC
| LEADER | 00000cam a22000007i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1289370803 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 008 | 211218t20222022enk ob 001 0 eng d | ||
| 040 | |a EBLCP |b eng |e rda |c EBLCP |d N$T |d OSU |d OCLCO |d OCLCF |d OCLCO |d OCLCQ |d OCLCO | ||
| 020 | |a 9781839165160 |q (electronic bk.) | ||
| 020 | |a 1839165162 |q (electronic bk.) | ||
| 020 | |z 9781839162633 |q (hbk.) | ||
| 020 | |z 1839162635 |q (hbk.) | ||
| 035 | |a (OCoLC)1289370803 | ||
| 050 | 4 | |a RS201.A56 | |
| 082 | 7 | |a 615.37 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Chemical linkers in antibody-drug conjugates (ADCs) / |c edited by Floris van Delft and John M. Lambert. |
| 264 | 1 | |a Cambridge : |b Royal Society of Chemistry, |c [2022] | |
| 264 | 4 | |c ©2022 | |
| 300 | |a 1 online resource (xvi, 460 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a ISSN | |
| 520 | |a The covalent conjugation of potent cytotoxic agents to monoclonal antibodies, known as antibody-drug conjugates (ADCs) is a powerful approach in the field of targeted treatment of cancer. Clearly, both monoclonal antibody and cytotoxic payload are crucial elements in determining the clinical value of an ADC and have receive ample attention. However, the structural element connecting the two -the chemical linker- also plays an essential role in mode-of-action, efficacy, pharmacokinetics and safety profile of an ADC, but is often underappreciated in considerations of ADC design.Chemical Linkers in Antibody-Drug Conjugates aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody ratio, for stability, for release mechanism of payload, for pharmacokinetics, for stability determination, and for efficacy and safety. Ideal for postgraduate students and active researchers in drug discovery and development, this book provides a comprehensive description of linkers used in ADCs (clinical and late preclinical), insight into key quality attributes of linkers for ADCs, and aids the reader in understanding the role of linker chemistry and designing new ADCs. | ||
| 504 | |a Includes bibliographical references and index | ||
| 505 | 0 | |a Introduction to antibody-drug conjugates / John M. Lambert and F. L. van Delft -- Antibody conjugation technologies / G. T. Hermanson and F. L. van Delft -- Linker design and impact on ADC properties / M. Frigerio and N. Camper -- Non-cleavable linkers: permanently linked, for better or for worse / Julien Dugal-Tessier and Nareshkumar Jain -- Protease-sensitive linkers / S. Johannes, A. Sommer and H.-G. Lerchen -- Acid-labile linkers / E. A. Savoy, F. P. Olatunji, H. Yoon, N. Mesbahi, J. R. Knight and C. E. Berkman -- ADC linkers strategies for the release of alcohol-containing payloads / Jared T. Miller and L. Nathan Tumey -- Click-cleavable ADC linkers / R. Rossin and M. S. Robillard -- The use of uniform PEG compounds in the design of ADCs / M. W. Giese, R. H. Woodman, G. T. Hermanson and P. D. Davis -- Enhancing the polarity of the linker-drug in ADCs / Jorin Hoogenboom and Sander S. van Berkel -- Trastuzumab deruxtecan targeting HER2-expressing cancers with a Dxd-ADC system consisting of a novel protease-sensitive linker and DNA topoisomerase I inhibitor with a hydroxyl group / Takashi Nakada, Yuki Abe and Toshinori Agatsuma | |
| 650 | 0 | |a Antibody-drug conjugates. |0 http://id.loc.gov/authorities/subjects/sh88000795 | |
| 650 | 6 | |a Conjugués anticorps-médicament. | |
| 650 | 7 | |a Antibody-drug conjugates |2 fast | |
| 700 | 1 | |a Delft, Floris L. van, |e editor. | |
| 700 | 1 | |a Lambert, John M., |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Chemical linkers in antibody-drug conjugates (ADCs). |d Cambridge : Royal Society of Chemistry, 2021 |z 9781839162633 |w (OCoLC)1276795013 |
| 830 | 0 | |a ISSN. | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3123142 |3 Volltext |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6827251 | ||
| 938 | |a EBSCOhost |b EBSC |n 3123142 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1289370803 |
|---|---|
| _version_ | 1816882554221887488 |
| adam_text | |
| any_adam_object | |
| author2 | Delft, Floris L. van Lambert, John M. |
| author2_role | edt edt |
| author2_variant | f l v d flv flvd j m l jm jml |
| author_facet | Delft, Floris L. van Lambert, John M. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RS201 |
| callnumber-raw | RS201.A56 |
| callnumber-search | RS201.A56 |
| callnumber-sort | RS 3201 A56 |
| callnumber-subject | RS - Pharmacy |
| collection | ZDB-4-EBA |
| contents | Introduction to antibody-drug conjugates / John M. Lambert and F. L. van Delft -- Antibody conjugation technologies / G. T. Hermanson and F. L. van Delft -- Linker design and impact on ADC properties / M. Frigerio and N. Camper -- Non-cleavable linkers: permanently linked, for better or for worse / Julien Dugal-Tessier and Nareshkumar Jain -- Protease-sensitive linkers / S. Johannes, A. Sommer and H.-G. Lerchen -- Acid-labile linkers / E. A. Savoy, F. P. Olatunji, H. Yoon, N. Mesbahi, J. R. Knight and C. E. Berkman -- ADC linkers strategies for the release of alcohol-containing payloads / Jared T. Miller and L. Nathan Tumey -- Click-cleavable ADC linkers / R. Rossin and M. S. Robillard -- The use of uniform PEG compounds in the design of ADCs / M. W. Giese, R. H. Woodman, G. T. Hermanson and P. D. Davis -- Enhancing the polarity of the linker-drug in ADCs / Jorin Hoogenboom and Sander S. van Berkel -- Trastuzumab deruxtecan targeting HER2-expressing cancers with a Dxd-ADC system consisting of a novel protease-sensitive linker and DNA topoisomerase I inhibitor with a hydroxyl group / Takashi Nakada, Yuki Abe and Toshinori Agatsuma |
| ctrlnum | (OCoLC)1289370803 |
| dewey-full | 615.37 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.37 |
| dewey-search | 615.37 |
| dewey-sort | 3615.37 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04062cam a22004457i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1289370803</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="008">211218t20222022enk ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">EBLCP</subfield><subfield code="d">N$T</subfield><subfield code="d">OSU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781839165160</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1839165162</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781839162633</subfield><subfield code="q">(hbk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1839162635</subfield><subfield code="q">(hbk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1289370803</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RS201.A56</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.37</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Chemical linkers in antibody-drug conjugates (ADCs) /</subfield><subfield code="c">edited by Floris van Delft and John M. Lambert.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge :</subfield><subfield code="b">Royal Society of Chemistry,</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xvi, 460 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">ISSN</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The covalent conjugation of potent cytotoxic agents to monoclonal antibodies, known as antibody-drug conjugates (ADCs) is a powerful approach in the field of targeted treatment of cancer. Clearly, both monoclonal antibody and cytotoxic payload are crucial elements in determining the clinical value of an ADC and have receive ample attention. However, the structural element connecting the two -the chemical linker- also plays an essential role in mode-of-action, efficacy, pharmacokinetics and safety profile of an ADC, but is often underappreciated in considerations of ADC design.Chemical Linkers in Antibody-Drug Conjugates aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody ratio, for stability, for release mechanism of payload, for pharmacokinetics, for stability determination, and for efficacy and safety. Ideal for postgraduate students and active researchers in drug discovery and development, this book provides a comprehensive description of linkers used in ADCs (clinical and late preclinical), insight into key quality attributes of linkers for ADCs, and aids the reader in understanding the role of linker chemistry and designing new ADCs.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Introduction to antibody-drug conjugates / John M. Lambert and F. L. van Delft -- Antibody conjugation technologies / G. T. Hermanson and F. L. van Delft -- Linker design and impact on ADC properties / M. Frigerio and N. Camper -- Non-cleavable linkers: permanently linked, for better or for worse / Julien Dugal-Tessier and Nareshkumar Jain -- Protease-sensitive linkers / S. Johannes, A. Sommer and H.-G. Lerchen -- Acid-labile linkers / E. A. Savoy, F. P. Olatunji, H. Yoon, N. Mesbahi, J. R. Knight and C. E. Berkman -- ADC linkers strategies for the release of alcohol-containing payloads / Jared T. Miller and L. Nathan Tumey -- Click-cleavable ADC linkers / R. Rossin and M. S. Robillard -- The use of uniform PEG compounds in the design of ADCs / M. W. Giese, R. H. Woodman, G. T. Hermanson and P. D. Davis -- Enhancing the polarity of the linker-drug in ADCs / Jorin Hoogenboom and Sander S. van Berkel -- Trastuzumab deruxtecan targeting HER2-expressing cancers with a Dxd-ADC system consisting of a novel protease-sensitive linker and DNA topoisomerase I inhibitor with a hydroxyl group / Takashi Nakada, Yuki Abe and Toshinori Agatsuma</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antibody-drug conjugates.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh88000795</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Conjugués anticorps-médicament.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antibody-drug conjugates</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Delft, Floris L. van,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lambert, John M.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Chemical linkers in antibody-drug conjugates (ADCs).</subfield><subfield code="d">Cambridge : Royal Society of Chemistry, 2021</subfield><subfield code="z">9781839162633</subfield><subfield code="w">(OCoLC)1276795013</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">ISSN.</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3123142</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL6827251</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">3123142</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1289370803 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:30:27Z |
| institution | BVB |
| isbn | 9781839165160 1839165162 |
| language | English |
| oclc_num | 1289370803 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xvi, 460 pages) |
| psigel | ZDB-4-EBA |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Royal Society of Chemistry, |
| record_format | marc |
| series | ISSN. |
| series2 | ISSN |
| spelling | Chemical linkers in antibody-drug conjugates (ADCs) / edited by Floris van Delft and John M. Lambert. Cambridge : Royal Society of Chemistry, [2022] ©2022 1 online resource (xvi, 460 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier ISSN The covalent conjugation of potent cytotoxic agents to monoclonal antibodies, known as antibody-drug conjugates (ADCs) is a powerful approach in the field of targeted treatment of cancer. Clearly, both monoclonal antibody and cytotoxic payload are crucial elements in determining the clinical value of an ADC and have receive ample attention. However, the structural element connecting the two -the chemical linker- also plays an essential role in mode-of-action, efficacy, pharmacokinetics and safety profile of an ADC, but is often underappreciated in considerations of ADC design.Chemical Linkers in Antibody-Drug Conjugates aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody ratio, for stability, for release mechanism of payload, for pharmacokinetics, for stability determination, and for efficacy and safety. Ideal for postgraduate students and active researchers in drug discovery and development, this book provides a comprehensive description of linkers used in ADCs (clinical and late preclinical), insight into key quality attributes of linkers for ADCs, and aids the reader in understanding the role of linker chemistry and designing new ADCs. Includes bibliographical references and index Introduction to antibody-drug conjugates / John M. Lambert and F. L. van Delft -- Antibody conjugation technologies / G. T. Hermanson and F. L. van Delft -- Linker design and impact on ADC properties / M. Frigerio and N. Camper -- Non-cleavable linkers: permanently linked, for better or for worse / Julien Dugal-Tessier and Nareshkumar Jain -- Protease-sensitive linkers / S. Johannes, A. Sommer and H.-G. Lerchen -- Acid-labile linkers / E. A. Savoy, F. P. Olatunji, H. Yoon, N. Mesbahi, J. R. Knight and C. E. Berkman -- ADC linkers strategies for the release of alcohol-containing payloads / Jared T. Miller and L. Nathan Tumey -- Click-cleavable ADC linkers / R. Rossin and M. S. Robillard -- The use of uniform PEG compounds in the design of ADCs / M. W. Giese, R. H. Woodman, G. T. Hermanson and P. D. Davis -- Enhancing the polarity of the linker-drug in ADCs / Jorin Hoogenboom and Sander S. van Berkel -- Trastuzumab deruxtecan targeting HER2-expressing cancers with a Dxd-ADC system consisting of a novel protease-sensitive linker and DNA topoisomerase I inhibitor with a hydroxyl group / Takashi Nakada, Yuki Abe and Toshinori Agatsuma Antibody-drug conjugates. http://id.loc.gov/authorities/subjects/sh88000795 Conjugués anticorps-médicament. Antibody-drug conjugates fast Delft, Floris L. van, editor. Lambert, John M., editor. Print version: Chemical linkers in antibody-drug conjugates (ADCs). Cambridge : Royal Society of Chemistry, 2021 9781839162633 (OCoLC)1276795013 ISSN. FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3123142 Volltext |
| spellingShingle | Chemical linkers in antibody-drug conjugates (ADCs) / ISSN. Introduction to antibody-drug conjugates / John M. Lambert and F. L. van Delft -- Antibody conjugation technologies / G. T. Hermanson and F. L. van Delft -- Linker design and impact on ADC properties / M. Frigerio and N. Camper -- Non-cleavable linkers: permanently linked, for better or for worse / Julien Dugal-Tessier and Nareshkumar Jain -- Protease-sensitive linkers / S. Johannes, A. Sommer and H.-G. Lerchen -- Acid-labile linkers / E. A. Savoy, F. P. Olatunji, H. Yoon, N. Mesbahi, J. R. Knight and C. E. Berkman -- ADC linkers strategies for the release of alcohol-containing payloads / Jared T. Miller and L. Nathan Tumey -- Click-cleavable ADC linkers / R. Rossin and M. S. Robillard -- The use of uniform PEG compounds in the design of ADCs / M. W. Giese, R. H. Woodman, G. T. Hermanson and P. D. Davis -- Enhancing the polarity of the linker-drug in ADCs / Jorin Hoogenboom and Sander S. van Berkel -- Trastuzumab deruxtecan targeting HER2-expressing cancers with a Dxd-ADC system consisting of a novel protease-sensitive linker and DNA topoisomerase I inhibitor with a hydroxyl group / Takashi Nakada, Yuki Abe and Toshinori Agatsuma Antibody-drug conjugates. http://id.loc.gov/authorities/subjects/sh88000795 Conjugués anticorps-médicament. Antibody-drug conjugates fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh88000795 |
| title | Chemical linkers in antibody-drug conjugates (ADCs) / |
| title_auth | Chemical linkers in antibody-drug conjugates (ADCs) / |
| title_exact_search | Chemical linkers in antibody-drug conjugates (ADCs) / |
| title_full | Chemical linkers in antibody-drug conjugates (ADCs) / edited by Floris van Delft and John M. Lambert. |
| title_fullStr | Chemical linkers in antibody-drug conjugates (ADCs) / edited by Floris van Delft and John M. Lambert. |
| title_full_unstemmed | Chemical linkers in antibody-drug conjugates (ADCs) / edited by Floris van Delft and John M. Lambert. |
| title_short | Chemical linkers in antibody-drug conjugates (ADCs) / |
| title_sort | chemical linkers in antibody drug conjugates adcs |
| topic | Antibody-drug conjugates. http://id.loc.gov/authorities/subjects/sh88000795 Conjugués anticorps-médicament. Antibody-drug conjugates fast |
| topic_facet | Antibody-drug conjugates. Conjugués anticorps-médicament. Antibody-drug conjugates |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3123142 |
| work_keys_str_mv | AT delftflorislvan chemicallinkersinantibodydrugconjugatesadcs AT lambertjohnm chemicallinkersinantibodydrugconjugatesadcs |